SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today announced that Sharon E. Tetlow, senior
vice president and chief financial officer of Cell Genesys, will present a
company update on Tuesday, March 18 at 8:00 a.m. ET at the Cowen and
Company 28th Annual Healthcare Conference in Boston, Massachusetts. Stephen
A. Sherwin, chairman and chief executive officer of Cell Genesys, will
present a company update on March 18 at 10:15 a.m. ET at the Lehman
Brothers 11th Annual Global Healthcare Conference in Miami, Florida.
A live audio webcast of both presentations will be accessible through
the Investor Relations section of the Cell Genesys website,
http://www.cellgenesys.com. If you are unable to listen to the live
webcast, it will be archived on the site for at least 72 hours following
the presentation. To access the replay, go to the Investor Relations
section of the website.
Cell Genesys is focused on the development and commercialization of
novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms -- GVAX(TM) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and
a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell
Genesys continues to hold an equity interest in its former subsidiary,
Ceregene, Inc., which is developing gene therapies for neurodegenerative
disorders. Cell Genesys is headquartered in South San Francisco, CA and has
its principal manufacturing operation in Hayward, CA. For additional
information, please visit the company's website at
http://www.cellgenesys.com.
Contact:
Susan Ferris
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Investor Relations, Susan Ferris of Cell
Genesys, Inc., +1-650-266-3200
|
